文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

乌干达多替拉韦时代孕产妇HIV-1耐药与母婴传播关联

HIV-1 drug resistance among pregnant and breastfeeding mothers and its association with paediatric HIV infections in the Dolutegravir era in Uganda.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

该研究纳入乌干达200名病毒载量>1000拷贝/mL的孕产妇,采用Illumina MiSeq进行基因型耐药检测。53.0%对至少一类抗逆转录病毒药物耐药,NNRTI耐药率41.5%,INSTI耐药率3.5%。D亚型及重复病毒载量监测与耐药突变相关,7名婴儿HIV-1阳性,母亲依从性差与重复病毒载量显著关联。

要点

  • 孕产妇HIVDRM负担高,53.0%对至少一类ART耐药。
  • INSTI耐药率3.5%, accessory突变T97A占13.5%。
  • D亚型与HIVDRM相关(P=0.01)。

核心结论

  • 高HIVDRM负担提示需常规耐药检测、亚型特异性治疗策略及加强依从性支持以减少母婴传播,尤其D亚型感染者。

研究设计与样本

  • 研究纳入46名孕妇和154名哺乳期母亲,均病毒载量>1000拷贝/mL,残留血浆用Illumina MiSeq平台进行基因型耐药检测。
  • HIVDRM和亚型用Stanford HIVdb算法判读,采用卡方检验、t检验和逻辑回归分析关联。

主要发现

  • 200名参与者中53.0%(95%CI: 46.0-59.9)对至少一类ART耐药。
  • HIVDRM患病率:NNRTI 41.5%(95%CI: 34.8-48.5),NRTI 20.5%(95%CI: 15.4-26.7),PI 4.0%(95%CI: 2.0-7.8),INSTI 3.5%(95%CI: 1.7-7.2)。
  • 13.5%存在辅助突变,包括可贡献DTG耐药的T97A。
  • HIV-1亚型A占57.0%,D占30.5%,C占6.5%,重组型占6.0%。
  • D亚型与HIVDRM相关(P=0.01),强化依从性咨询后常规/重复病毒载量监测与HIVDRM相关(P=0.04)。

临床怎么用

  • 对病毒载量>1000拷贝/mL的孕产妇应考虑基因型耐药检测以指导治疗。
  • 对D亚型感染者需加强耐药监测和依从性支持。
  • 重复病毒载量监测结合强化依从性咨询可能有助于降低母婴传播。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the prevalence and patterns of HIV drug resistance mutations among pregnant and breastfeeding women in Uganda following the rollout of dolutegravir, characterize circulating HIV-1 subtypes and their association with resistance, and identify factors associated with vertical HIV transmission. MATERIALS AND METHODS: This study involved 46 pregnant and 154 breastfeeding mothers in Uganda with viral loads (VLs) >1000 copies/mL. Residual plasma underwent genotypic resistance testing on the Illumina MiSeq platform, and HIVDRMs and subtypes were interpreted using the Stanford HIVdb algorithm. Participant characteristics were summarized descriptively, and associations between subtypes, HIVDRMs, and vertical transmission were assessed using chi-square tests, t-tests, and logistic regression. RESULTS: Among 200 participants, 53.0% (95% CI: 46.0-59.9) had resistance to at least one antiretroviral therapy (ART) class. HIVDRM prevalence was 41.5% (CI: 34.8-48.5) for NNRTIs, 20.5% (CI: 15.4-26.7) for NRTIs, 4.0% (CI: 2.0-7.8) for PIs and 3.5% (CI: 1.7-7.2) for INSTIs. Notably, 13.5% had accessory mutations, including T97A, which can contribute to DTG resistance. HIV-1 subtypes A (57.0%) and D (30.5%) were most common, with few subtype C (6.5%) and recombinant forms (6.0%). Subtype D and routine/repeat VL monitoring following intensive adherence counselling were associated with HIVDRMs (P = 0.01 and P = 0.04 respectively). Seven infants tested HIV-1 positive, with poor maternal adherence and repeat VL significantly associated with seropositivity (P = 0.004 and P = 0.027, respectively). CONCLUSION: This high HIVDRM burden highlights the urgent need for routine resistance testing, subtype-specific treatment strategies and improved ART adherence support to reduce mother-to-child-transmission, particularly in women with subtype D infections.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Kapaata A, Byamukama D, Kankaka EN, et al. HIV-1 drug resistance among pregnant and breastfeeding mothers and its association with paediatric HIV infections in the Dolutegravir era in Uganda. J Antimicrob Chemother. 2026. PMID: 41221803. doi:10.1093/jac/dkaf411

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。